Session II Clinical Studies of Pimozide
The major tranquillizers have in common the ability to interfere with dopaminergic blockade, either by blocking post-synaptic dopamine receptors or by diminishing the release of dopamine presynaptically. Yet the clinical actions of these drugs are still disputed. I shall review some of the controversy and suggest a simple, perhaps simplistic, way of viewing the clinical modes of action of these important drugs.
The names given to these drugs demonstrate the lack of concensus on the type of action, as various authorities have denigrated them as 'chemical straitjackets' or extolled them as 'antischizophrenic agents', revolutionizing the outlook of this distressing condition. The latter term begs the question of what is schizophrenia and merely expresses one unknown in terms of another. The rubric 'major tranquillizer' suggests a powerful calming effect and there is no doubt that these drugs can pacify almost all disturbed patients.
Unwanted neurological effects, especially on the extrapyramidal system, are common and have led to the term 'neuroleptic', particularly popular in Europe where psychiatry has often not yet undergone its schism from neurology. The increasing concern over tardive dyskinesia suggests that neurological effects will remain an important problem. 'Ataractic' just means tranquillizer and is infrequently used. Other terms follow the fashion to label drugs as 'anti' something. Depending on the beliefs of the user, these drugs are labelled 'anti-schizophrenic', more generally, 'anti-psychotic' or even 'antihallucinatory'.
Acute Schizophrenia
Standard text-books of clinical pharmacology tend to concentrate on the acute tranquillizing effects of these drugs rather than on any possible action on the schizophrenic process.
Perhaps the discoverers of chlorpromazine who must have observed their patients minutely can help? Delay and his co-workers (1952) described Dr M H Lader its remarkable action on states of excitation, anxiety and insomnia, that is, a non-specific tranquillizing effect.
In the earliest reports from North America, Heinz Lehmann (1954) a meticulous observer, described chlorpromazine as possessing 'the rather unique property of producing sedation without affective disinhibition and significant intellectual clouding'. He saw new vistas opening in psychiatry, but as he nowhere mentions schizophrenia, presumably this was not in his field of view.
However, 10 years later, phenothiazines were being extensively evaluated in acute schizophrenia. One large American study challenged the concept of these drugs as tranquillizers: 'Almost all symptoms and manifestations characteristic of schizophrenic psychoses improved with drug therapy, suggesting that the phenothiazines should be regarded as "antischizophrenic" in the broad sense' (NIMH Collaborative Study Group, 1964) .
Conversely, Domino (1968) stated baldly: 'it is commonly recognized that these agents control the secondary symptoms of schizophrenia' (hallucinations, motor and autonomic hyperactivity) whereas the primary symptoms (thought disorder, alteration in affect etc.) were only secondarily improved. In the same volume, 15 pages on, Cole & Davis (1968) interpreted their data as indicating that the differential effect of phenothiazines as opposed to placebo was more striking on the fundamental symptoms of schizophrenia. Nevertheless, despite such differences in emphasis, there seems little doubt that the major tranquillizers lessen psychopathology in patients with acute schizophrenic breakdowns. There also seems little doubt that they effectively diminish psychopathology in any psychotic patientthe agitated depressive, the manic and the brain-damaged. In our present state of knowledge, there seems too little justification for labelling these drugs 'anti-schizophrenic' and perhaps rather more for dubbing them 'antipsychotic'.
Schizophrenic Relapse
However, schizophrenia is more than an acute psychotic breakdown. Do the major tranquillizers prevent relapse? If they do then the term 'maintenance therapy' is justified.
The earlier studies on the prevention of relapse were mainly from the USA. One series of studies suggested that chronic schizophrenic patients treated with chlorpromazine could be maintained longer in the community than comparable patients on placebo (Engelhardt et al. 1964 ). Eventually the same proportion, 40% of both groups, was admitted to hospital, but not until the patients on the phenothiazine had been out of hospital for an average period 18 months longer than the placebo patients.
Conflicting results were obtained by Pasamanick et al. (1964) who found that not only did longterm treatment with chlorpromazine result in a longer period of extramural life than with placebo, but that the superiority of the drug tended to increase with time. After 30 months, 77% of the drug-treated patients had remained continuously in the community, as compared with only 34 % of the placebo group (Dinitz et al. 1965) . A complicating factor in such'studies is that an undetermined proportion of patients who relapse either discontinue their drugs or reduce their dosage. Some cease taking their drugs and then relapse. Others become more ill and then decide to stop their drugs.
The two most relevant British studies emanated from the MRC Social Psychiatry Unit. In the first, a placebo-controlled double-blind trial, the use of phenothiazines during 1 year of maintenance therapy in a selected group of schizophrenic outpatients was significantly more effective than placebo in preventing relapse (Leff & Wing 1971) . Despite this, about one-third of those patients known to be regularly taking active drug relapsed. The patients selected by their consultants to enter the trial were of inter-mediate prognosis. Most of those patients given a good prognosis remained well, without any drugs. Most given a bad prognosis relapsed, despite maintenance therapy. Within the intermediate group, those likely to remain well were in the first episode of illness with an acute onset; their symptoms included those of 'endogenous' despression and they had a good pre-morbid personality. Thus, this trial not only suggested which patients might benefit from maintenance treatment, but also those in whom drug treatment, with its attendant risks of long-term adverse effects, could be safely withheld.
The second study showed a high relapse rate among chronic schizophrenic patients well established on long-acting fluphenazine injections who were switched to placebo (Hirsh et al. 1973 ). The relapse rate among patients who continued on active medication was only 8 % over 9 months and about double this over 13 months. In the relapsing patients, florid symptoms increased and the strain on their relatives became greater.
The factors governing the propensity to relapse have been teased out in a series of studies from the MRC Social Psychiatry Unit, the latest study being published last year (Vaughn & Leff, 1976) . Data were available from a total of 128 schizophrenic patients maintained in the community. The overall relapse rate in 9 months was 30%. The patient's home environment was categorized as high Ekpressed Emotion (EE) or low EE depending on the number of critical, hostile and emotionally overinvolved comments made by the key relative about the patient during a standardized interview. Life events of an 'independent' nature i.e. those outside the patient's control, also seem important. Such life events tend to cluster in the ineffective in combatting the effects of major life events.
Chronic Schizophrenia
There seems general agreement that maintenance therapy with major tranquillizers lessens the likelihood of a florid relapse in chronic schizophrenic patients. The evidence that these drugs lessen the chronic symptoms of schizophrenia is much less compelling. One complication is that many of these patients are immured in asylums and many of their difficulties may reflect years of institutionalization, rather than a continuing disease problem.
Patients with chronic paranoid schizophrenia with otherwise intact intellectual and emotional functioning are generally considered to show the best response, often being maintained in an essentially normal state. By contrast, drugs are often of limited effectiveness in anergic, retarded, affectively flat patients.
A Common Mode ofAction?
The tranquillizing effects of the major tranquillizers in acute states of disturbed behaviour can be explained in terms of lowering excessive arousal levels. Observation of acutely psychotic patients (agitated, manic, delirious, etc.) accords with simple explanations of nervous system overactivity or overarousal and psychophysiological recordings from such patients are consistent with this interpretation. The overwhelming advantage of the major tranquillizers over the older sedatives such as paraldehyde, the narcotics and the barbiturates, is the absence of excitatory actions in low doses and the maintenance of clear consciousness at high doses. Presumably, by dopaminergic blockade, the major tranquillizers interfere with arousal and psychomotor mechanisms which do not subserve consciousness.
Can the effect of the major tranquillizers in schizophrenia also be explained in such basically simple terms? In the acutely disturbed, the tranquillizers are effective in quietening the patient, especially if the drug is given parenterally. The onset of improvement in the less severely ill is often unpredictable, sometimes being delayed for a few weeks, at other times occurring after a few dose administrations. Also, there seems little correlation between clinical response and plasma concentrations (Kane 1976) . One speculation is that the overarousal state is self-sustaining and that the drug breaks into a vicious circle mechanism. Once interrupted,the psychotic episode subsides whether further drug therapy is maintained or not.
The work mentioned earlier suggests that patients deemed of poor prognosis tend to relapse despite drugs, those of good prognosis stay well without drugs and drug effects are only important in the intermediate group. The social features such as high EE homes, lengthy face-toface contact with the key relative and independent life events are all interpretable as increasing arousal. Indeed, we have psychophysiological data to support this view (Tarrier et al. 1977) .
Drugs are only effective in the aroused, i.e. the high EE subjects and even here, they are less effective in the severely overaroused, especially when life events supervene. Thus, one could speculate that 'maintenance therapy' protects the schizophrenic patient from states of medium overarousal but it is not powerful enough to protect the grossly overaroused.
Finally, in the chronic schizophrenic, some symptoms are helped but in general overarousal is not such that a tranquillizing effect is useful. Nor is there any evidence that the natural history of schizophrenia has been materially altered by the major tranquillizers. More patients live in the community but they still tend to relapse. Readmission, by removing them from an overarousing environment, is itself therapeutic in providing the environment in which the drugs can break the vicious circle postulated earlier. Nonetheless, patients still become chronic although the social and personal consequences of repeated relapse may be ameliorated.
This simple overarousal hypothesis views schizophrenia as a condition (or more probably a series of conditions) which leads to a central nervous state of susceptibility to overarousal. If the propensity is marked, e.g. a markedly positive family history, breakdown will readily occur. If the propensity is minimal (i.e. the 'good' premorbid personality) the arousing stimuli must be powerful and some would term the breakdown 'schizophreniform' rather than truly schizophrenic.
What the mechanisms are which underlie this susceptibility, i.e. the schizophrenic 'process', are a complete mystery. However, I believe that by separating the breakdowns from the continuing process, conceptual and heuristic progress can be made. If so, then study of the major tranquillizers may tell us something about psychotic breakdowns, but sadly perhaps, nothing about schizophrenia.
